A Walk in the PARP: Therapeutic Strategies Targeting DNA Repair Defects in Prostate Cancer

Watch this CME-certified on-demand Webcast of a CCO symposium at ASCO GU 2019 to gain expert perspectives on the evolving role of PARP inhibitors in advanced prostate cancer, including an overview of BRCA and other DNA repair deficiencies, guidance on genetic testing, review of the latest clinical data, and a panel case discussion.
Celestia Higano Headshot
Celestia S. Higano, MD, FACP
David A. Quigley, PhD
Charles J. Ryan, MD
Released: March 20, 2019 Expiration: No longer available for credit

Related Content

Downloadable slideset reviewing the latest data on immunotherapy for patients with newly diagnosed advanced urothelial carcinoma, from Clinical Care Options (CCO)

person default Thomas Powles, MBBS, MRCP, MD Released: September 21, 2020

Downloadable slideset on the latest data on treatment for patients with progressive urothelial carcinoma and insights on new horizons for immunotherapy in urothelial carcinoma, from Clinical Care Options (CCO)

person default Alain Ravaud, MD, PhD Released: September 21, 2020

Commentary from Elizabeth R. Plimack, MD, MS on new treatment options, including erdafitinib and enfortumab vedotin, for urothelial cancer from CCO

Elizabeth R. Plimack, MD, MS Released: September 15, 2020

From ASCO 2020: analysis by Daniel P. Petrylak, MD, and Elizabeth R. Plimack, MD, MS, of key studies in renal cell carcinoma, urothelial carcinoma, and prostate cancer from CCO

Daniel P. Petrylak, MD Elizabeth R. Plimack, MD, MS Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: September 1, 2020 Expired: August 31, 2021
Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by educational grants from
AstraZeneca
Clovis Oncology
Pfizer Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue